Key facts
- It has raised $16.7M; the latest was Grant ($3.7M) in Sep 2025.
- Notable investors include ANRI, IRDI Capital Investissement, France 2030, Matwin, Ministere De La Culture — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Phost'in Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Phost'in Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phost'in Therapeutics
Developer of chemical entities designed to put an emphasis on the treatment of abnormal glycosylation mechanisms and cancer. The company's chemical entities specialise in the discovery and development of NCEs targeting pathogenic glycosylation mechanisms, enabling medical providers to effectively deal with cancer and other serious illnesses.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2014
- Employees
- 15
- Website
- phostin.com/
- Ownership
- Privately Held (backing)
Phost'in Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phost'in Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phost'in Therapeutics in its N-PORT filings yet. We sweep new filings monthly.